[DUSP2]
Mutation tier
| Entity | Tier |
|---|---|
| DLBCL | 1 |
| FL | 2 |
Mutation incidence
| Entity | study | frequency (%) |
|---|---|---|
| DLBCL | GAMBL genomes | 9.30 |
| DLBCL | Schmitz cohort | 12.60 |
| DLBCL | Reddy cohort | 9.70 |
| DLBCL | Chapuy cohort | 4.30 |
| FL | GAMBL genomes | 2.31 |
Mutation pattern
| Entity | aSHM | Significant selection | dN/dS (missense) | dN/dS (nonsense) |
|---|---|---|---|---|
| BL | Yes | No | 1.258 | 17.913 |
| DLBCL | Yes | No | 1.537 | 12.012 |
| FL | Yes | No | 3.206 | 0.000 |
aSHM regions
| chr_name | hg19_start | hg19_end | region | regulatory_comment |
|---|---|---|---|---|
| chr2 | 96808901 | 96811913 | intron-1 | enhancer |
[!NOTE] First described in DLBCL in 2017 by Reddy A
Citing
If you use the information or data from this site, please cite
Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.
Disclaimer
The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.
